# Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers

> **NCT00703807** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 10 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT00703807
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703807, "Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00703807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*